To identify the miRNA candidates as potential therapeutic targets, we overlapped our microarray data with a male NSCLC TCGA dataset containing the miRNA expression profiles from the tumor tissue, followed by validation at the plasma level of one miRNA candidate (miR-34c-5p) and the EGFR level of expression in the serum samples. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.